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To assess dissemination of OXA-23–producing strains 
of Acinetobacter baumannii, we obtained 20 carbapenem-
resistant, OXA-23–producing isolates from different regions. 
Their clonal relationship was assessed by pulsed-ﬁ  eld gel 
electrophoresis and multilocus sequence typing. We identi-
ﬁ  ed 8 sequence types, including 4 novel types. All except 2 
strains belonged to 2 main European clonal lineages. The 
blaOXA-23 gene was either located on the chromosome or on 
plasmids and associated with 4 genetic structures.
A
cinetobacter baumannii is a gram-negative organism 
that is increasingly recognized as a major pathogen 
causing nosocomial infections, including bacteremia and 
ventilator-associated pneumonia, particularly in patients 
admitted to intensive care units (1). Several studies have 
shown the geographically widespread occurrence of mul-
tidrug-resistant A. baumannii strains, which suggested a 
clonal relatedness of these strains. Three international A. 
baumannii clones associated with multidrug resistance 
(European clones I, II, and III) have been reported (2).
Increasing resistance to carbapenems has been ob-
served worldwide in the past decade, frequently mediated 
by production of class D β-lactamases with carbapenemase 
activity. Three acquired class D β-lactamases with carbap-
enemase gene clusters have been described in A. bauman-
nii, which correspond to blaOXA-23-like, blaOXA-40-like, and 
blaOXA-58-like genes (3). The blaOXA-23 gene, ﬁ  rst character-
ized in Scotland (4), has been increasingly reported world-
wide. A. radioresistens was recently identiﬁ  ed as the pro-
genitor of the blaOXA-23-like genes (5). Clonal outbreaks of 
carbapenem-resistant and OXA-23–producing A. bauman-
nii have been reported in many countries, such as Bulgaria 
(6), People’s Republic of China (7), Brazil (8), Iraq (9), 
Afghanistan (9), and French Polynesia (10).
Genetic acquisition of the blaOXA-23 gene was investi-
gated and transposons Tn2006, Tn2007, and Tn2008 were 
identiﬁ  ed as genetic structures harboring this gene (10–12). 
In Tn2006, the blaOXA-23 gene is ﬂ  anked by 2 copies of the in-
sertion sequence ISAba1, which are located in opposite ori-
entations (Figure 1). The functionality of Tn2006 has been 
recently demonstrated (13). Tn2008 is similar to Tn2006 
but lacks the second copy of ISAba1 and the blaOXA-23 gene 
is associated with 1 copy of ISAba4 (which differs from 
ISAba1) in Tn2007 (Figure 1) (11). As reported for strains 
from United Arab Emirates and Bahrain, the blaOXA-23 gene 
can be associated with only 1 copy of ISAba1 (14,15). We 
studied the clonal relationship and genomic environment of 
sequences surrounding the blaOXA-23 gene among a collec-
tion of OXA-23–producing isolates from 15 countries.
Materials and Methods
Bacterial Strains and Susceptibility Testing
Twenty OXA-23–producing A. baumannii clinical iso-
lates were obtained from 15 countries. These isolates had 
been obtained from patients hospitalized in intensive care 
units from December 2003 through March 2008. Isolates 
were obtained from tracheal aspirates (n = 3), bile (n = 
1), urine (n = 4), wounds (n = 1), respiratory tract (n = 1), 
blood (n = 4), and sputum (n = 1). The isolates were initial-
ly chosen after preliminary pulsed-ﬁ  eld gel electrophoresis 
(PFGE)–based typing had identiﬁ  ed 13 pulsotypes. Isolates 
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were obtained from France (n = 4), Vietnam (n = 1), New 
Caledonia (n = 1), Thailand (n = 1), Australia (n = 1), Tahiti 
(n = 1), Reunion (n = 2), South Africa (n = 1), United Arab 
Emirates (n = 2), Libya, (n = 1), Bahrain (n = 1), Egypt (n = 
1), Belgium (n = 1), Algeria (n = 1), and Brazil (n = 1).
Presence of the blaOXA-23 gene was screened by 
PCR by using speciﬁ   c primers (OXA-23-A 5′-GGA
ATTCCATGAATAAATATTTTACTTGC-3′ and OXA-
23-B 5′-CGGGATCCCGTTAAATAATATTCAGGTC-3′) 
and additional sequencing (ABI 3100 sequencer; Applied 
Biosystems, Foster City, CA, USA). Susceptibility pat-
terns to β-lactam antimicrobial drugs were determined by 
using a standard disk diffusion method according to pub-
lished standards (16) and Etest strips (AB Biodisk, Solna, 
Sweden). Isolates were identiﬁ  ed by using 16S rRNA gene 
sequencing (17).
Clonal Relationships
Isolates were typed by using ApaI macrorestriction 
analysis and PFGE according to the manufacturer’s recom-
mendations (Bio-Rad, Marnes-la-Coquette, France). Bac-
teria were grown in a medium appropriate for the strain 
until an optical density of 0.8 to 1 at 600 nm was reached. 
One milliliter of cells was centrifuged, washed, and resus-
pended in 10 mmol/L Tris, pH 7.2, 20 mmol/L NaCl, 50 
mmol/L EDTA. Immediately after resuspension, an equal 
volume of 2% low melting point InCert agarose (Bio-Rad) 
was added. Solid agarose plugs were lysed at 37°C for 2 h 
in 1 mL of lysis buffer (10 mmol/L Tris, pH 7.2, 50 mmol/L 
NaCl, 0.5% sodium laurylsarcosine, 0.2% sodium deoxy-
cholate) supplemented with 20 mg/L of lysozyme. The 
plugs were then incubated at 55°C for 16 h with proteinase 
K buffer (100 mmol/L EDTA, pH 8, 0.2% sodium deoxy-
cholate, 1% sodium laurylsarcosine) supplemented with 20 
mg/L of proteinase K. Plugs were washed with Tris-EDTA 
buffer containing 1 mmol/L phenylmethylsulfonyl ﬂ  uoride 
(Sigma, St. Louis, MO, USA) and 3× with Tris-EDTA buf-
fer at room temperature.
Whole-cell DNA of A. baumannii isolates was digest-
ed with ApaI overnight at room temperature (New England 
Biolabs, St. Quentin-en-Yvelines, France). Electrophoresis 
was performed on a 1% agarose gel with 0.5× Tris-borate-
EDTA buffer by using a CHEF DRII apparatus (Bio-Rad). 
Samples were subjected to electrophoresis at 14°C, 6 volts/
cm, and a switch angle with 1 linear switch ramp of 3–8 s 
for 10.5 h, and then for 12–20 s for 10.5 h.
Identiﬁ   cation of PCR-based sequence groups was 
conducted by using 2 multiplex PCR assays designed to 
selectively amplify group 1 or group 2 alleles of the gene 
encoding outer-membrane protein A (ompA), the gene en-
coding part of a pilus assembly system required for bioﬁ  lm 
formation (csuE), and the gene encoding the intrinsic car-
bapenemase gene of A. baumannii) (blaOXA-51) (18). Clonal 
relationships were established by multilocus sequence typ-
ing (MLST) by using 7 standard housekeeping loci (citrate 
synthase [gltA], gyrase B [gyrB], glucose dehydrogenase 
B [gdhB], recombination A [recA], chaperone 60 [cpn60], 
glucose-6-phosphate isomerase [gpi], and RNA poly-
merase [rpoD]) as described (18). Sequencing of internal 
fragments was performed by using BigDye ﬂ  uorescent 
terminators and primers described (19). Sequences were 
compared with the A. baumannii database at the MLST 
Website (http://mlst.zoo.ox.ac.uk). To supplement epide-
miologic results, we performed a second MLST typing us-
ing the scheme developed by Nemec et al. (20). Sequences 
of the 7 housekeeping genes were analyzed by using an A. 
baumannii database (www.pasteur.fr/recherche/genopole/
PF8/mlst/Abaumannii.html).
Southern Blot Analysis and Location of blaOXA-23 Gene
Southern blot analysis was performed by using total 
genomic DNA digested with EcoRI, separated by electro-
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Figure 1. Genetic structures associated 
with the blaOXA-23 gene of Acinetobacter 
baumannii. A) Tn2006 from isolates 240, 
512, 810, 859, 883 and AUS (ST22/ST2). 
B) Tn2008 from isolate 614. C) Tn2007 from 
isolates Ab14, BEL, and DOS. D) ISAba1 
from isolates AS3, 1190, 861, and 877. 
Boundaries of Tn2006, Tn2007, and Tn2008 
are indicated with the target site duplication 
likely generated by transposition events 
underlined. The 7-bp difference in the site of 
insertion of ISAba1 for isolate 614 is double-
underlined. The open reading frame 1 (orf1), 
orf2, and orf3 genes of unknown function is 
indicated.  tnpA, gene encoding a putative 
transposase;  ATPase, gene encoding 
the putative AAA  ATPase; DEAD, gene 
encoding the putative DEAD (Asp-Glu-Ala-
Asp) helicase; DNAmethyl, DNA methylase.Carbapenemase Gene of A. baumannii
phoresis on 0.8% agarose gels, transferred onto Hybond 
N+ membranes, and hybridized with enhanced chemilu-
minescence labeled probes overnight at 42°C. The mem-
branes were developed according to the manufacturer’s 
instructions (GE Healthcare, Saclay, France). Chromosom-
al or plasmid locations of the β-lactamase gene were as-
sessed by hybridization of I-CeuI–digested genomic DNA 
with blaOXA-23 and 16S rDNA probes and electrophoresis 
(20–120 s for 9 h and 60–100 s for 11 h at 14°C and 5 V/
cm2) (21). DNA was transferred from an agarose gel to a 
nylon membrane by capillary transfer. Hybridization, la-
beling, and detection were conducted as described above. 
Mating-out assays were performed by using isolates that 
had plasmid-borne blaOXA-23 as donors and rifampin-resis-
tant A. baumannii BM4547 as recipients as described (22). 
Transconjugants were selected on trypticase soy agar plates 
containing ticarcillin (50 mg/L) and rifampin (50 mg/L).
Cloning Experiments
To identify entire transposon structures containing the 
blaOXA-23 gene in different isolates and determine their lo-
cation in the target DNA, a cloning procedure was used. 
Some data had been reported for 6 of 20 isolates (11). Total 
DNA was digested with either SacI or SalI, ligated into the 
SacI or SalI sites of plasmid pBK-CMV (kanamycin-resis-
tant cloning vector), and the recombinant plasmids were 
transformed into Escherichia coli TOP10, as described 
(14). Recombinant plasmids were selected on trypticase 
soy agar plates containing amoxicillin (50 mg/L) and ka-
namycin (30 mg/L). Cloned DNA fragments of several re-
combinants plasmids were sequenced on both strands by 
primer walking as described (11).
Results
Clonal Relatedness of the Isolates
Twenty carbapenem-resistant A.  baumannii isolates 
were obtained from 15 countries (Table). All isolates were 
highly resistant to ticarcillin (MIC >256 mg/L) and showed 
a high level of resistance to ceftazidime (MIC >256 mg/L), 
except isolates Ab14 (MIC 4 mg/L) 861 and DOS (MIC 8 
mg/L). All isolates were resistant to imipenem and mero-
penem (MIC >16 mg/L) (Table).
Multiplex PCR for identiﬁ  cation of sequence groups 
showed 10 isolates that belonged to group 1 according to 
Turton et al. (18), eight that belonged to group 2, and 2 
isolates that did not belong to groups 1 or 2. The 10 isolates 
that belonged to group 1 and corresponded to European 
clone II (18) were classiﬁ  ed into 2 sequence types (STs), 
ST22 and ST53, according to MLST analysis (18). ST22 
(1–3-3–2-2–7-3) was the most frequent type identiﬁ  ed. 
Nine isolates were identiﬁ  ed: 2 from France and 1 each 
from Vietnam, New Caledonia, Thailand, Australia, Ta-
hiti, Reunion, and South Africa. A single European clone 
II isolate was classiﬁ  ed as ST53 (1–3-3–2-2,3-3), a single-
locus variant of ST22. Among 10 other isolates, 8 belonged 
to group 2 (corresponding to European clone I). Four STs 
were identiﬁ  ed: ST25 (10–12–4–11–1–9–5) (Libya, United 
Arab Emirates, and Bahrain), ST44 (10–12–4–11–4–9–5) 
(United Arab Emirates and Algeria), and 2 new STs, 1 for 
isolates from Reunion and Egypt (10–12–4–11–4–16–5) 
and another related ST identiﬁ  ed in the single isolate from 
Belgium (10–12–4–11–4,4–5). These 4 STs differ by 1 lo-
cus. The 2 most recent isolates from France and Brazil did 
not belong to European clones I or II and corresponded to 2 
STs (1–22–3-11–1-9–7 and 12–18–12–1-15–9-19, respec-
tively) (Table). Although 8 STs were identiﬁ  ed in this col-
lection, 9 pulsotypes were characterized by PFGE accord-
ing to the criteria of Tenover et al. (23) (Figure 2).
According to MLST analysis developed by Nemec et 
al. (20), all isolates that belonged to European clone II had 
the same sequence type (ST2) (2,2-2,2-2,2-2), including 
isolate 585, which had a distinct but related ST in the ﬁ  rst 
analysis. Among isolates that belonged to European clone 
I, two sequence types were determined: ST20 (3–1-1,1-5–
1-1) (Libya, United Arab Emirates, Bahrain) and ST1 (1,1-
1,1-5–1-1) (United Arab Emirates, Reunion, Egypt, Bel-
gium, Algeria). Isolates 910 (Reunion), 861 (Egypt), and 
BEL (Belgium) were included in ST1. These isolates had a 
distinct ST according to methods of Bartual et al. (19). The 
2 most recent isolates were classiﬁ  ed into 2 STs, a new ST 
(3–2-2,2-5–4-8) for isolate DOS (France) and ST15 (6,6-8
–2-3–5-4) for isolate 877 (Brazil) (Table).
Location and Transferability of the blaOXA-23 Gene
Location of the blaOXA-23 gene was evaluated by using 
the I-CeuI method. Eleven isolates had the blaOXA-23 gene 
on the chromosome, with a hybridization signal for an ≈40-
kb band for isolate AS1 and an ≈200-kb band for 10 iso-
lates (Table). Nine isolates carried the blaOXA-23 gene on a 
plasmid and 1 isolate had 2 copies of the blaOXA-23 gene, 1 
on the chromosome and 1 on a 7–kb plasmid (Table).
To examine the copy number of the blaOXA-23 gene in 
different A. baumannii genomes, we performed Southern 
blot hybridization on EcoRI-digested DNA fragments us-
ing a 589-bp DNA probe speciﬁ  c for the blaOXA-23 gene. 
Sixteen isolates showed only 1 copy of the blaOXA-23 gene. 
Isolates BEL, Ab14, and DOS had 2 copies of the blaOXA-23 
gene on different plasmids, and Ab13 had 1 copy on the 
chromosome and 1 copy on a plasmid according to results 
of the I-Ceu1 technique.
Mating-out assays were performed by using the 10 
plasmid-positive strains as donor strains and rifampin-re-
sistant A. baumannii BM4547 as the recipient strain. Five 
transconjugants were obtained; all had a 130-kb plasmid 
that did not provide additional antimicrobial drug resistance 
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to the A. baumannii recipient strain, except in 1 case (co-re-
sistance to kanamycin and amikacin on a blaOXA-23–carrying 
plasmid that originated from isolate 1190). Plasmids carry-
ing the blaOXA-23 gene in isolates Ab14, DOS, BEL, and 877 
were not self-transferable (Table) (24).
Variability of Genetic Structures Flanking the blaOXA-23 
Gene
The 10 isolates that belonged to European clone II had 
a blaOXA-23 gene that was part of Tn2006. The 9-bp direct 
repeat (DR) that corresponded to duplication of the Tn2006 
target site, which was consistent with a transposition event, 
was identiﬁ  ed in the 9 ST22/ST2 isolates. Tn2006 was in-
serted in different locations on the chromosomes of those 
isolates (Table). For isolates 240, 512, 810, 859, 883, and 
Aus, the insertion occurred between 2 genes encoding hy-
pothetical proteins (DR: GTCATTTAA) (Figure 1). In iso-
late 761, transposon Tn2006 was located between a gene 
encoding a hypothetical protein and a gene encoding an 
isoleucyl tRNA synthase (DR: ATTCGCGGG). In isolate 
863, Tn2006 was identiﬁ  ed between a gene encoding a cy-
tochrome D terminale oxidase and a putative transposase 
(DR: ATAATTATT). In isolate 585, Tn2006 was located 
between a gene encoding a hypothetical protein and a sul1 
gene (DR: ATTCGCGGG). The plasmid-borne blaOXA-23 
gene identiﬁ  ed in isolate Ab13 was also part of Tn2006 but 
was inserted into the sul gene that encoded a putative sul-
fonamide resistance determinant (DR: ATTCGCGGG).
Isolates that belonged to European clone I had diverse 
genetic structures at the origin of blaOXA-23 acquisition. Two 
isolates had transposon Tn2006: one on the chromosome 
(AS1) and 1 on a plasmid (910). Transposon Tn2007 was 
identiﬁ  ed in 3 isolates; it was speciﬁ  c for the same open 
reading frame in 2 isolates (BEL and Ab14) (Figure 2). 
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isolation Specimen EC ST†
Copy no. of 
blaOXA-23
Genetic location 
and size, kb 
Genetic
structure  CAZ IPM MEM
240 France 2003 Dec  Tracheal
aspirate
II 22/2 1 Chromosome,
|200‡
Tn2006 128 >32 >32
512 Tahiti 2004 Mar  Tracheal
aspirate
II 22/2 1 Chromosome,
|200‡
Tn2006 64 >32 >32
761 Vietnam 2005 May  Bile II 22/2 1 Chromosome,
|200‡
Tn2006 64 >32 >32
810 New 
Caledonia
2004 Jun  Blood II 22/2 1 Chromosome,
|200‡
Tn2006 96 >32 >32
863 Thailand 2006 Jun  Urine II 22/2 1 Chromosome,
|200‡
Tn2006 256 >32 >32
883 Reunion 2006 Jun  Unknown  II 22/2 1 Chromosome,
|200‡
Tn2006 128 >32 >32
Ab13 France 2004 Jun  Urine II 22/2 2 Chromosome,
|200,‡ and 
plasmid, 70 
Tn2006 128 >32 >32
AUS Australia 2004 Oct  Urine II 22/2 1 Chromosome,
|200‡
Tn2006 96 >32 >32
859 South
Africa
2006 Jan  Urine II 22/2 1 Chromosome,
|200‡
Tn2006 128 >32 >32
585 France 2004 Jul  Tracheal
aspirate
II 53/2 1 Chromosome,
|200‡
Tn2006 128 >32 >32
614 Libya  2004 Oct  Unknown  I 25/20 1 Plasmid, 130  Tn2008 256 >32 16
AS3 UAE† 2006 Oct  Blood I 25/20 1 Plasmid, 130  ISAba1 256 >32 >32
1190 Bahrain 2008 Mar  Blood I 25/20 1 Plasmid, 130  ISAba1 256 >32 >32
AS1 UAE 2006 Jul  Blood I 44/1 1 Chromosome,
|40‡
Tn2006 256 >32 >32
Ab14 Algeria 2004 Dec  Unknown  I 44/1 2 Plasmid, 25, and 
plasmid, >150 
Tn2007 41 6 > 3 2
910 Reunion 2006 Oct  Unknown  I New1/1  1 Plasmid, 130  Tn2006 256 16 16
861 Egypt  2005 Nov  Sputum I New1/ 1  1 Plasmid, 130  ISAba1 83 2 3 2
BEL Belgium 2007 Jul  Respiratory 
tract
I New2/ 1  2 Plasmid, 25, and 
plasmid, >150 
Tn2007 256 >32 >32
DOS France 2004 May  Unknown  – New3/ 
New 
2 Plasmid, 25, and 
plasmid, >150 
Tn2007 8> 3 2 > 3 2
877 Brazil 2006 Jul  Wound – New4/15  1 Plasmid, 130  ISAba1 96 >32 >32
*EC, European clone; ST, sequence type; UAE, United Arab Emirates; CAZ, ceftazidime; IPM, imipenem; MEM, meropenem. The MIC for ticarcillin was 
>256 ȝg/mL for all 20 isolates. 
†ST determined by Bartual et al. (19) compared with ST determined by Nemec et al. (20). 
‡Size of chromosome band carrying the blaOXA-23 gene, as determined by using the I-CeuI technique. Carbapenemase Gene of A. baumannii
Only 1 copy of ISAba1 was identiﬁ  ed upstream of the 
blaOXA-23 gene in isolates AS3, 1190, 861, and 877. Trans-
poson Tn2008 was identiﬁ  ed only in isolate 614 (Figure 1). 
Sequences of these speciﬁ  c genetic structures have been de-
posited in Genbank (accession nos. EF127491, EF059914, 
GQ861438, and GQ861439).
Discussion
This study was conducted to deﬁ  ne which features 
may explain the worldwide dissemination of the blaOXA-23 
gene in A. baumannii. Isolates were from the Middle East, 
Europe, and Asia; there were no isolates from North Amer-
ica. Except for 2 isolates, the isolates investigated in this 
study belonged to European clones I or II. Clustering of A. 
baumannii isolates was determined by MLST and PFGE; 
our collection was composed of 13 PFGE types corre-
sponding to 9 STs. Eight STs were identiﬁ  ed among the 
OXA-23–producing A. baumannii; the most common STs 
were ST22/ST2 found in France (n = 2), Vietnam, New 
Caledonia, Thailand, Australia, Reunion, South Africa, and 
Tahiti. Spread of blaOXA-23–positive A. baumannii isolates 
that belong to clone ST22 has been demonstrated in South 
Korea (25). Analysis of the target site of blaOXA-23 acquisi-
tion showed that in the same clone, such as ST22, acquisi-
tion of the Tn2006 composite transposon had occurred at 
different positions in the A. baumannii genome, which sug-
gested that Tn2006-mediated acquisition of blaOXA-23 may 
occur as independent events, or that Tn2006 is a structure 
that is mobile in a given genome. A single clone could have 
different genetic structures at the origin of the blaOXA-23 ac-
quisition.
We showed that the blaOXA-23 gene associated with 
Tn2006 could be located on the chromosome or a plasmid. 
This result agrees with our recent ﬁ  ndings, which showed 
that Tn2006 is capable of transposition (13). We have also 
observed that 5 isolates with different sequence types (ST-
New1, ST25) harbored a similar 130-kb plasmid. The same 
strains with the same genetic structure were identiﬁ  ed in 8 
countries in different parts of the world.
In conclusion, the current worldwide dissemination of 
the blaOXA-23 gene is driven by >7 MLST types associated 
with different genetic structures and plasmids. We have 
identiﬁ  ed complex and dynamic spreading of blaOXA-23 that 
will be difﬁ  cult to control because this spread is not associ-
ated with a single entity.
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